SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to immediate market uncertainty surrounding an anticipated speech by Donald Trump at Davos, sparking community debate over potential tariffs and geopolitical tensions, particularly regarding Greenland. Sentiment is split, with some traders concerned about rising Japanese bond yields and broader market weakness, while others expect a rebound, highlighting underlying economic resilience and a potential rotation into small-cap and value stocks.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is seeing a significant surge in conversation, driven by recent reports of high-grade silver and gold drill results and continued accumulation by mining billionaire Eric Sprott. The community is intensely divided, with many anticipating a substantial short squeeze and linking its prospects to a booming precious metals market, while others caution about potential dilution and the company's lack of current production.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW) is currently a trending multi-chain meme coin, garnering significant attention as its community emphasizes its deflationary mechanics and organic cult-like growth across Solana, Cronos, and Base. Enthusiasts are actively discussing its potential to bring substantial volume to various chains and are anticipating further developments like staking opportunities, positioning it as a formidable player in the meme coin sector.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid reports of Berkshire Hathaway potentially divesting its substantial stake and recent analyst downgrades, sparking intense debate among investors. Many see current price levels as an exceptional buying opportunity, citing a strong dividend and an anticipated company split to unlock value, while skeptics warn of a value trap given persistent competition and past performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck & Co., Inc. $MRK Stock Position Boosted by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 34.3% in the third quarter, according to the company in its most recent 13F filing with the SEC...

Dynasty Wealth Management LLC Takes $1.02 Million Position in Merck & Co., Inc. $MRK

Dynasty Wealth Management LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange...

<ul class="summary-bullets"><li>BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares.</li><li>The update followed the release of five-year follow-up results for the Intismeran vaccine used alongside Keytruda in melanoma patients.</li><li>Moderna and Merck said additional data from the study will be shared at an upcoming medical meeting.</li></ul>Moderna Inc. shares were in focus on Wednesday after Bank of America Securities (BofA) raised its price target on the stock following new long-term data from the company’s experimental skin cancer vaccine developed with Merck, while keeping a bearish rating in place.Merck shares rose 0.6% in regular trading before slipping 0.6% after hours, while Moderna climbed 2.8% during the session and edged 0.2% lower in extended trading.<h2 class="st-heading-2">Price Target Raised, Rating Maintained</h2>BofA raised its price target on Moderna to $27 from $24 and reiterated an ‘Underperform’ rating on the shares. However, based on Moderna’s last closing price of $43, the updated target&nbsp;still implies about a 37% downside.The firm said the increase followed the release of five-year data for Intismeran Autogene, Moderna’s personalized cancer vaccine, used in combination with Merck’s Keytruda in patients with high-risk melanoma.While noting some upside potential, the brokerage pointed to challenges seen in similar combination treatments in the past, logistical challenges, and a “higher bar for success.” BofA said the higher price target reflects increased sales expectations for the vaccine in patients who have undergone surgery for melanoma.<h2 class="st-heading-2">Five-Year Skin Cancer Results</h2>Moderna and Merck said the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">latest follow-up</a> showed the vaccine combination continued to help patients remain cancer-free for longer than Keytruda alone.After five years, patients who received the combination saw a 49% lower risk of the cancer returning or leading to death than those treated with Keytruda by itself. The companies said the findings build on earlier updates shared at the two-year and three-year marks. Moderna and Merck also said they plan to share additional follow-up results at an upcoming medical meeting.<h2 class="st-heading-2">Oncology Pipeline Progress</h2>“Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination in patients with resected high-risk melanoma,” said Kyle Holen, Moderna’s head of oncology development.Holen said the company continues to invest in cancer research and is preparing for several upcoming milestones, including results from a late-stage melanoma study being run with Merck, as well as progress across eight ongoing studies in different cancer types. Meanwhile, Merck’s head of oncology, Marjorie Green, said the long-term results are encouraging for patients&nbsp;at high risk of the disease returning after surgery.Moderna said it is continuing to expand its cancer treatment work alongside its vaccine business. The company and Merck are currently running or enrolling studies across several cancers, including lung, bladder, kidney, and melanoma, as part of their joint development program for the vaccine.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘neutral’ for Moderna and ‘bearish’ for Merck, with both seeing ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_65694a07b3.webp" alt="mrna ss.png" width="969" height="140"><figcaption>MRNA sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/mrk_ss_png_42eb55ab2c.webp" alt="mrk ss.png" width="961" height="141"><figcaption>MRK sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has risen 26% over the past 12 months, while Merck’s stock has jumped 16% over the same period.&nbsp;On Wall Street, analysts are largely neutral on MRNA, according to Koyfin data: 17 out of 24 analysts covering the stock recommend a ‘hold’ rating, while four have a ‘buy’ or ‘strong buy’ conviction, and the rest have a ‘sell’ rating. Their consensus price target of $​​36.75 leaves MRNA trading at a more than 14% premium.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Equity

Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen raised their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a "hold" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up as well as three years of follow-up.</li><li>Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.</li><li>Moderna is currently seeking to pivot into oncology and rare-disease therapeutics.</li></ul>Moderna (MRNA) and Merck (MRK) said on Tuesday that their intismeran autogene vaccine based on messenger RNA (mRNA), in combination with cancer drug Keytruda, reduced the risk of recurrence or death by 49% in certain patients with high-risk melanoma on five years of follow-up when compared to Keytruda alone.The improvement was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=7585547225835569&amp;symbol=MRNA">observed</a> in patients with stage III/IV melanoma who had complete removal of their tumors. Melanoma is a serious form of skin cancer characterized by the uncontrolled growth of pigment-producing cells.Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.<h2 class="st-heading-2">Executives’ Take</h2>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up, as well as three years of follow-up, the companies said."We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA's potential in cancer care. We look forward to several additional milestones to come, including the results of our Phase 3 study in adjuvant melanoma in collaboration with Merck, and continued progress across the eight Phase 2 and Phase 3 studies in multiple tumor types and patient populations," Moderna's Senior Vice President and Head of Development of Oncology and Therapeutics Kyle Holen said.Moderna is currently seeking to pivot into oncology and rare-disease therapeutics. "Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">said</a> in November.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, as per the firm.Shares of MRNA traded 1.1% higher at the time of writing while MRK stock traded marginally in the red.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume dipped from ‘extremely high’ to ‘high’ levels.Meanwhile, sentiment around MRK shares stayed within the ‘neutral’ territory, coupled with ‘normal’ message volume.A Stocktwits user opined that the news is “solid” for Moderna’s oncology segment.<stembedurl>https://www.stocktwits.com/MobyOneCanobi/message/642290058</stembedurl>Another user voiced hopes for the stock crossing the $50/share price this week.<stembedurl>https://www.stocktwits.com/Raven67/message/642288562</stembedurl><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained 18% over the past 12 months while <a href="https://stocktwits.com/symbol/MRK">MRK shares</a> have gained 13%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mu-stock-analyst-target-hikes-how-much-upside-does-retail-expect/cmUuYEzR4Ob">MU Stock Garners Attention Amid Analyst Target Hikes — How Much Upside Does Retail Expect?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update

Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 

Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?

Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.

Turtle Creek Wealth Advisors LLC Cuts Position in Merck & Co., Inc. $MRK

Turtle Creek Wealth Advisors LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 68.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange...

CytomX Stock Rises 31% in a Month: Here's What You Should Know

CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.

NorthCrest Asset Manangement LLC Buys 81,276 Shares of Merck & Co., Inc. $MRK

NorthCrest Asset Manangement LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing...

Wealth Enhancement Advisory Services LLC Acquires 98,009 Shares of Merck & Co., Inc. $MRK

Wealth Enhancement Advisory Services LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.9% in the third quarter, according to its most recent Form 13F filing with the...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$2.02	--	--	N/A
Q3 '25	$2.35	$2.58	9.90%	BEAT
Q2 '25	$2.02	$2.13	5.40%	BEAT
Q1 '25	$2.13	$2.22	3.99%	BEAT
Q4 '24	$1.61	$1.72	6.96%	BEAT

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest MRK News

MRKMerck & Co Inc